Skip to main content

Table 3 SOGUG Guideline compliance according to treatment

From: Impact on clinical practice of the implementation of guidelines for the toxicity management of targeted therapies in kidney cancer. The protect-2 study

  Sunitinib
977
Sorafenib
247
Pazopanib
210
Everolimus
166
Temsirolimus
125
Bevacizumab
24
Total
1,858
  Pre
534
Post
443
Pre
157
Post
90
Pre
1
Post
209
Pre
130
Post
145
Pre
56
Post
69
Pre
14
Post
10
Pre
892
Post
966
Overall compliance, n cycles (%)
Yes 136 (25.5) 123 (27.8) 17 (10.8) 2 (2.2)* 0 (0.0) 68 (32.5) 42 (32.3) 67 (46.2)* 8 (14.3) 17 (24.6) 3 (21.4) 0 (0.0) 206 (23.1) 277 (28.7)*
No 398 (75.5) 320 (72.2) 140 (89.2) 88 (97.8) 1 (100) 141 (67.5) 88 (67.7) 78 (53.8) 48 (85.7) 52 (75.4) 11 (78.6) 10 (100) 686 (76.9) 689 (71.3)
Guidelines compliance by adverse event, n cycles (%)a
Hypertension 173 (43.5) 171 (53.4)* 1 (0.7) 0 (0.0) 0 (0.0) 69 (48.9) 9 (81.8) 9 (90.0) 183 (33.3) 249 (44.5)£
Cardiac toxicity 113 (28.4) 87 (27.2) 113 (28.4) 87 (27.2)
Skin toxicity 398 (100) 320 (100) 140 (100) 88 (100) 48 (100) 52 (100)- 586 (100) 460 (100)
Hypothyroidism 172 (43.2) 157 (49.1) 172 (43.2) 157 (49.1)
Diarrhea 274 (68.8) 264 (82.5)£ 124 (88.6) 73 (83.0) 1 (100) 105 (74.5) 399 (74.0) 442 (80.5)*
Hyperglycemia 63 (71.6) 53 (67.9) 28 (58.3) 39 (75.0) 91 (66.9) 92 (70.8)
Dyslipemia 22 (25.0) 42 (53.8) £ 12 (25.0) 16 (30.8) 34 (25.0) 58 (44.6)#
Pneumonitis 53 (60.2) 42 (53.8) 31 (64.6) 32 (61.5) 84 (61.8) 74 (56.9)
Liver toxicity 1 (100) 37 (26.2) 1 (100) 37 (26.2)
Proteinuria 2 (18.2) 0 (0.0) 2 (18.2) 0 (0.0)
  1. a (%): percentage of compliance in relation to the total cycles in which the SOGUG guidelines were not-complied with
  2. *p between groups <0.05; # p between groups <0.001; £ p between groups <0.0001. Length of cycles according to routine clinical practice: sunitinib 6 weeks; other treatments 4 weeks
\